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DNA methylation associated with
postpartum depressive symptoms overlaps
findings from a genome-wide association
meta-analysis of depression
Dana M. Lapato1,2* , Roxann Roberson-Nay2,3, Robert M. Kirkpatrick2,3, Bradley T. Webb2,3, Timothy P. York1,2,4† and
Patricia A. Kinser5†
Abstract
Background: Perinatal depressive symptoms have been linked to adverse maternal and infant health outcomes.
The etiology associated with perinatal depressive psychopathology is poorly understood, but accumulating
evidence suggests that understanding inter-individual differences in DNA methylation (DNAm) patterning may
provide insight regarding the genomic regions salient to the risk liability of perinatal depressive psychopathology.
Results: Genome-wide DNAm was measured in maternal peripheral blood using the Infinium MethylationEPIC
microarray. Ninety-two participants (46% African-American) had DNAm samples that passed all quality control
metrics, and all participants were within 7 months of delivery. Linear models were constructed to identify
differentially methylated sites and regions, and permutation testing was utilized to assess significance. Differentially
methylated regions (DMRs) were defined as genomic regions of consistent DNAm change with at least two probes
within 1 kb of each other. Maternal age, current smoking status, estimated cell-type proportions, ancestry-relevant
principal components, days since delivery, and chip position served as covariates to adjust for technical and
biological factors. Current postpartum depressive symptoms were measured using the Edinburgh Postnatal
Depression Scale. Ninety-eight DMRs were significant (false discovery rate < 5%) and overlapped 92 genes. Three of
the regions overlap loci from the latest Psychiatric Genomics Consortium meta-analysis of depression.
Conclusions: Many of the genes identified in this analysis corroborate previous allelic, transcriptomic, and DNAm
association results related to depressive phenotypes. Future work should integrate data from multi-omic platforms
to understand the functional relevance of these DMRs and refine DNAm association results by limiting phenotypic
heterogeneity and clarifying if DNAm differences relate to the timing of onset, severity, duration of perinatal mental
health outcomes of the current pregnancy or to previous history of depressive psychopathology.
Keywords: DNA methylation, Perinatal depressive psychopathology, Epigenome-wide association study,
Differentially methylated regions, Major depression
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Introduction
Perinatal depressive symptoms can occur any time dur-
ing pregnancy or shortly following birth and even sub-
clinical levels of depressive symptoms have been
associated with an increased risk for episodes of major
depression with onset in the peripartum (MDP), preg-
nancy complications, maternal suicide, and adverse in-
fant health outcomes and development [1–7]. The
Diagnostic and Statistical Manual (fifth edition; DSM-5)
classifies MDP as a major depressive episode that occurs
during pregnancy or within 4 weeks of delivery [8]; how-
ever, in practice, researchers and clinicians may extend
this period to up to one year postpartum. Attempts to
understand the impact of depressive psychopathology on
biological mechanisms have primarily centered on eluci-
dating the relationship between maternal mental health
and negative infant outcomes. As a result, relatively little
is known regarding how perinatal depressive symptoms
affect maternal biological processes. Epidemiological
studies suggest that episodes of major depression (MD)
may increase the risk for other adverse health outcomes,
such as cardiovascular disease, and perturb immune sys-
tem activities. The biological pathways associated with
these persistent changes in immune activity and elevated
risk have not yet been identified. More work is needed to
uncover the pathways underlying these comorbidities and
to determine if the biological impact from depressive
symptoms differs by clinical subtype (e.g., perinatal and
early-onset). One potential avenue for understanding bio-
logical changes associated with depressive psychopath-
ology is through DNA methylation (DNAm) studies.
DNAm is a chemical modification typically found on
cytosines bordering guanines (i.e., cytosine-phosphate-
guanine [CpG] sites). DNAm can influence gene expres-
sion, genomic stability, and chromatin conformation [9].
Inter-individual differences in DNAm have been associ-
ated with early mortality [10], cancer [11], imprinting
disorders [12, 13], childhood trauma exposure [14], bio-
logical age [15, 16], and schizophrenia [17, 18]. Associa-
tions between DNAm and clinical MD and/or depressive
symptoms proximal to [19–22] or absent pregnancy
[23–26] have been reported; however, most of the peri-
natal depression studies have focused on identifying
DNAm patterns in fetal tissues associated with maternal
mental health, leaving a significant knowledge gap. Char-
acterizing the relationship between DNAm and perinatal
depressive symptoms may provide insight regarding the
pathoetiology of MDP as well as potentially identify bio-
logical markers [27].
This study sought to identify DNAm patterns associ-
ated with perinatal depressive symptoms during the first
7 months postpartum in maternal blood focusing on re-
gional DNAm changes. Genome-wide DNAm and re-
peated measures of maternal mental health were
collected as part of a longitudinal study of preterm birth
[28]. The rationale for focusing on differentially methyl-
ated regions (DMRs) rather than single CpG site associa-
tions was twofold. One, regional changes are thought to
represent differences more likely to be biologically
meaningful and statistically credible [29]. A single CpG
site associated with a trait could be spurious; however,
multiple CpG sites within one region each associating
with a trait in the same direction is likely to represent a
more robust finding. Two, regional analyses reduce the
burden of multiple tests and allow one to test for smaller
probe effect sizes [30]. The sample size for this study is
acceptable to test regional differences, but it is not well-
powered to identify individual probe associations.
Methods
Study participants
The data for this analysis come from the Pregnancy,
Race, Environment, Genes (PREG) study and its postpar-
tum extension [28]. Both PREG and the extension re-
ceived IRB approval, and all participants provided
written informed consent for both parts. Most partici-
pants had the first postpartum visit within 3 months of
delivery and the second visit within 9 months. The
PREG study recruited an epidemiological sample of
women in early pregnancy primarily from two health
clinics in Richmond, Virginia. The purpose of the PREG
study was to identify factors that influence racial health
disparities in preterm birth. The postpartum study ex-
tension permitted additional perinatal outcomes, like
perinatal depression, to be investigated.
Study eligibility criteria
PREG study enrollment criteria required participants to
(1) be < 24 weeks gestation, (2) have a singleton preg-
nancy, (3) have not used artificial reproductive technol-
ogy for the current pregnancy, (4) be between 18 and 40
years old, and (5) be absent of major health conditions
(e.g., diabetes) [28]. Additionally, the participant and the
biological father had to self-identify as either both
African-American or both European-American and
without Middle Eastern or Hispanic ancestry. Birth ex-
clusion criteria included chromosomal or amniotic ab-
normalities (e.g., polyhydramnios/oligohydramnios) and
congenital birth defects.
Psychiatric assessments
Current perinatal depressive symptoms were measured
at both postpartum study visits using the Edinburgh
Postnatal Depression Scale (EPDS) [31]. The EPDS is a
10-item self-report instrument that is used in clinical
practice to screen for probable perinatal depression and
in research to assess for perinatal depressive symptoms;
it differs from other depressive symptom measures
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because the items focus on symptoms specifically related
to depression that would not be part of a typical preg-
nancy [32]. For example, difficulty sleeping is common
in pregnancies regardless of maternal MD status. EPDS
total score was analyzed as a continuous variable. Scores
of 13 or more out of 30 indicate probable perinatal de-
pression [31].
Genome-wide DNAm measurement and processing
Maternal genome-wide DNAm was assayed according to
the manufacturer’s protocol (Illumina, San Diego, CA,
USA) from peripheral blood using the EPIC beadchip,
which includes more than 850,000 probes and interro-
gates regulatory, genic, and intergenic regions [33].
Blood samples were collected in EDTA tubes at each
study visit along with health questionnaires. An aliquot
of 1 μg DNA per participant was sent to HudsonAlpha
Laboratories for DNAm measurement. Samples were
randomized to arrays to minimize potential batch effects
related to processing influencing DNAm patterns. Per-
ipheral blood was selected given its accessibility, the
availability of cell-type deconvolution methods, and the
strong evidence of immune system involvement in MDP
pathophysiology [34–37].
Raw microarray data was processed using Bioconduc-
tor packages in the R environment in line with best
practices [38–40] (version 3.5). Signal intensity and
probe failure rate were evaluated using the minfi [41]
package to identify poor quality samples and probes.
Samples were removed if either the median unmethy-
lated or methylated signal intensities were less than 10.5.
Probes were removed if they failed in > 1% of samples (n
= 12,557), overlapped single-nucleotide polymorphisms
(SNPs; n = 30,435), or had been identified as cross-
hybridizing in the Illumina Infinium HumanMethyla-
tion450 beadchip (predecessor technology) [42]. Probes
on the sex chromosomes were retained given that the
entire sample was female, leaving a total of 782,884
probes. All samples were quantile normalized, and blood
cell type proportions were estimated using the House-
man method [43]. Sample identity was confirmed using
the 59 control probes on the EPIC beadchip. These
probes overlap polymorphic sites and in aggregate can
estimate sample relatedness and detect sample duplica-
tion. All pairwise sample correlations were calculated.
Any sample correlated too poorly with its sister samples
(r < 0.8) or too highly with samples from another person
(r > 0.6) were removed or relabeled if the correct iden-
tity could be ascertained. Only one blood sample per
person was used for this analysis. In general, DNAm
samples from the first postpartum visit were used; how-
ever, if a participant’s first postpartum visit failed quality
control and she had a second postpartum DNAm sam-
ple within 7 months of delivery, then that sample and
the EPDS questionnaire from the same visit was used.
For all participants, the phenotypic and DNAm data
were from the same study visit. The purpose for using
only one sample was to capture the postpartum time
period with the highest estimates of depressive symptom
prevalence while also limiting potential phenotypic het-
erogeneity [44–46].
DNAm analysis
Covariate selection
Maternal age, number of days postpartum at blood and
questionnaire collection, smoking status, and microarray
row were selected as covariates a priori based on known
or putative associations with DNAm. Principal compo-
nent analysis (PCA) was applied to the normalized me-
thyl values [47] of the filtered probe set, and correlations
between the top ten principal components (PC) and
technical and biological variables were plotted to identify
additional potential confounders. Four variables (esti-
mated granulocyte proportion, chip size, self-reported
census-based race category, and slide ID number) corre-
lated greater than the absolute value of 0.5 with at least
one PC. Slide effects were addressed using ComBat [48].
Genetic ancestry relevant PCs were calculated with the
Barfield method [49]. Two PCs strongly independently
correlated with self-identified race were included instead
of self-identified race because the PCs have been shown
to adjust for genomic inflation better than a categorical
variable [49]. These two components also correlated
strongly with estimated blood cell proportions (r > than
the absolute value of 0.5). Estimated granulocyte propor-
tion also was included as a covariate to provide add-
itional adjustment for cell-type heterogeneity.
Identifying single-site and regional DNAm changes
The methyl values for individual probes were regressed
onto postpartum EPDS total score using the limma
package [50]. Covariates controlling for row, granulocyte
proportion, median unmethylated signal intensity mater-
nal age, gestational age at blood collection, smoking sta-
tus, and allelic ancestry were included. The strength of
the association between individual probes and EPDS
total score was evaluated using empirical p values de-
rived from a null distribution derived from the dataset
itself (k = 20,000 permutations). This analysis strategy
provides a more appropriate assessment and adjustment
for test statistic inflation than a metric like lambda [51].
The median effect size for probes used in the DMR ana-
lysis was assessed using the difference in adjusted R2
values between the full model and a reduced model
without EPDS total score.
The probes with the largest observed t statistics (top
and bottom 2.5% of tested probes) were used for re-
gional analysis. Differentially methylated regions (DMRs)
Lapato et al. Clinical Epigenetics          (2019) 11:169 Page 3 of 13
were defined as contiguous regions of consistent DNAm
change (i.e., all hypermethylated or all hypomethylated)
that contained at least two probes within 1 kb using a
method similar to that described by Ong and Holbrook
[30]. This strategy is similar to the DMRcate algorithm
in that only the subset of the probes with the best evi-
dence for association is used to construct DMRs [52].
DMR significance was assessed using a rank-based
permutation strategy and an empirical null distribution
derived from k = 1000 permutations. DMRs were con-
structed from both the observed data and 1000 of the
20,000 DMP permutation sets. For each DMR, the area
under the curve (AUC) was calculated using the trapez-
oidal rule, where each probe’s t statistic served as height
and the distance between the probes as width. Thus, the
magnitude of the AUC reflects both the strength of each
probe’s association (height) and the size of the region
(width). The significance of analysis microarray (SAM)
method was implemented to assign test statistics to each
observed DMR [53]. This method ranks all DMRs gener-
ated within a permutation by AUC and performs row-
wise comparisons between the ranked observed DMRs
and the ranked permutation DMRs to calculate a false
discovery rate (FDR).
Gene set enrichment and comparison to other genetic
findings related to depression
DMPs and DMRs were annotated using AnnotationHub
[54]. Gene set enrichment testing for functional and
regulatory roles was performed on the combined dataset
of DMPs and DMRs using Entrez IDs and clusterProfiler
[55]. The rationale for combining DMRs and DMPs into
a single group for gene set analysis was to address the
issue that not all probes are capable of forming DMRs.
In order to give those regions of the genome an oppor-
tunity to contribute to gene set enrichment analysis,
DMPs and DMRs were analyzed together (see Additional
file 1 for full enrichment analysis of the combined
DMR-DMP analysis as well as the DMP-only and DMR-
only enrichment analyses performed separately with
clusterProfiler [55] and methylGSA [56]).
The results from this analysis were compared directly
to two studies of depression: the latest Psychiatric Gen-
omics Consortium (PGC) meta-analysis of genome-wide
association studies of depression and an epigenome-
wide association study (EWAS) of early-onset MD. For
the PGC study, the 44 significant loci were obtained to
determine the extent of overlap with significant DNAm
regions [57]. Bootstrap and permutation methods (k =
1000) were used to test if DNAm regions were enriched
for PGC loci. For the early-onset MD EWAS, site, re-
gional, and gene enrichment results from the Adolescent
and Young Adult Twin Study (AYATS) were compared
to findings from this study to determine the extent of
overlap and similarity [26, 85].
Results
Sample characteristics
Sample demographics can be found in Table 1 and are
representative of Richmond, Virginia. Approximately
half of the participants (46%) self-identified as African-
American, and the mean gestational age was 274.5 days
(sd = 13.0 days). Most of the women (65%) were primi-
gravida and had full-term pregnancies (94%). Very few
participants were current smokers (8%), and 18% of the
total sample self-reported a positive lifetime history of
MD. Lifetime MD history did not significantly predict
postpartum EPDS score, and the distribution of EPDS
scores by self-reported MD history are in Additional file 5:
Figure S3. The average EPDS score was 5.4, and 13 partici-
pants (14%) scored 13 or greater on the EPDS. The aver-
age time between delivery and postpartum study visit was
57 days (see Additional file 5).
Differentially methylated probes and regions
After microarray quality control and processing, 782,884
probes remained for analysis. From this filtered probe
set, it was possible to create up to 109,340 background
DMRs. N = 206,804 probes were ineligible to participate
in regional analyses because they did not have a neigh-
boring probe within 1 kb. Individual site analysis of the
entire probe set identified 50 DMPs significantly associ-
ated with EPDS total score (empirical p = 0 after 20,000
Table 1 PREG-PPD sample characteristics
Demographics
Total N 92
African-American (%) 42 (45.7)
Age 29.7 (4.4)
Early gestation BMI 27.4 (7.3)
First pregnancy (%) 59 (64.8)
Gestational length (days) 274.5 (13.0)
Preterm birth (%) 6 (6.5)
Days postpartuma 56.5 (36.7)
Current smoker (%) 7 (7.6)
Depressive phenotypes
Positive lifetime history of MD (%)b 16 (18.0)
Current postpartum depressive symptom loadc 5.4 (5.9)
PREG-PPD Pregnancy, Race, Environment, Genes study Postpartum Extension;
MD major depression
*All values are mean (standard deviation) unless otherwise noted with '(%)' to
indicate N (%) or 'N' to indicate count. Percentages were calculated using
valid responses
aNumber of days postpartum when study visit (i.e., blood draw and
questionnaire collection) occurred
bAssessed using the Composite International Diagnostic Interview-Short Form
cAssessed using the Edinburgh Postnatal Depression Scale
Lapato et al. Clinical Epigenetics          (2019) 11:169 Page 4 of 13
permutations; see Additional file 5 for DMP quantile-
quantile plot). Approximately 39,150 probes were taken
forward for regional analysis. The median difference in
adjusted R2 values for the full versus reduced models for
these probes was 0.053 (interquartile range = 0.02).
Ninety-eight genomic regions spanning a collective
116.2 kb were significantly differentially methylated by
postpartum depressive symptom load (FDR < 5%). The
significant regions overlapped 92 genes on 20 chromo-
somes (none on chromosomes 7 or 18), and on average
spanned ~ 1.2 kb in length (see Additional file 2 for full
DMR gene list). The number of CpG probes in signifi-
cant DMRs ranged from 2 to 10 (mean = 3.48 probes).
Gene set enrichment and comparison of DNAm patterns
associated with postpartum depressive symptoms and
other genetic findings related to depression
Detailed results for the combined gene set enrichment of
DMPs and DMRs can be found in Table 2. In short, the
combined analysis identified one biological process (BP;
cognition) and four cellular components (CC; DNA repair
complex, neuron to neuron synapse, axon part, and syn-
apse part) significant at an FDR < 5%. The DMP and
DMR only analyses did not identify any categories with an
FDR < 5% and produced dissimilar results (see Additional
file 1). The DMP only analysis identified multiple BP and
CC categories associated with neural processes (e.g., cen-
tral nervous system neuron development, transmission of
nerve impulses, somatodendritic compartment, and neur-
onal cell body), and the significance of these categories
was markedly attenuated using a gene enrichment algo-
rithm that adjusts for number of probes per gene [56].
The DMR only analysis returned Gene Ontology (GO)
categories from a variety of biological systems, including
platelet formation and morphogenesis, cardiac muscle tis-
sue development, chemical synaptic transmission, inflam-
matory cell apoptotic process, and tissue morphogenesis.
Three DMRs overlapped PGC GWAS findings on chro-
mosomes 5, 6, and 16 (p = 0.034; see Additional file 3 for
more detail). The overlapping region on chromosome 6
occurred in the major histocompatibility complex (MHC)
region and neighbored genomic areas previously associ-
ated with early-onset major depression (DNAm) [26] and
depression as defined in the PGC genome-wide allelic
meta-analysis (see Fig. 1) [57]. None of the sites or regions
identified in the AYATS EWAS of early-onset major de-
pression directly overlapped the DMRs associated with
postpartum depressive symptom load in this analysis
[26]. The DMR with the largest AUC was located on
chromosome 15 and spanned five CpG sites (Fig. 2).
Discussion
Evaluating the credibility and replicability of the signifi-
cant findings from this analysis is paramount but
complicated. Few directly comparable studies exist, and
standardized practices for conducting and reporting re-
sults from epigenome-wide association studies (EWAS)
have not been established. That said, domains to assess
the credibility of EWAS results have been proposed, in-
cluding the level of statistical significance, genomic loca-
tion, biological relevance, functional relevance, validation
of significant associations, and the potential for study de-
sign bias or confounding variables to influence the ana-
lysis [29]. An indirect effect of evaluating the results
with these criteria is that it also highlights a study’s
strengths and weaknesses.
This study identified 98 DMRs and 50 DMPs using
DNAm measures from the EPIC beadchip (850 k), one
of the most comprehensive microarray technologies
available to assay DNAm. The combination strategy of
site- and region-based analysis identified significant re-
sults that overlap a gene set enriched for biological path-
ways highly relevant to putative depression etiology (e.g.,
synaptic signaling and dendrite development). Moreover,
the significant genome regions include a number of
genes that have been previously associated with MD
(e.g., RNF145 [59]) or with estrogen and progesterone
signaling (e.g., FOXA1, ARRB2, and ITGB3BP), which
may be particularly relevant for MDP and perinatal de-
pressive symptom risk liability [37]. None of the sites or
regions from this directly overlapped regions significant
in the AYATS EWAS of early-onset MD [26]; however,
both this study and the AYATS EWAS identified signifi-
cant DNAm regions in the major histocompatibility
complex (MHC) region on chromosome 6, which was
also identified in the latest PGC GWAS of depression
[57]. The two DNAm studies also shared a large propor-
tion of Gene Ontology (GO) terms in their respective
gene set enrichment analyses (e.g., synaptic transmission
and central nervous system development), suggesting
that even if the exact sites differed by study, the bio-
logical pathways with associated genes did not.
Comparing these results within the DNAm-MDP lit-
erature is difficult because a majority of the studies used
candidate gene approaches, which perform best as
methods to refine results from genome-wide analyses.
The only other genome-wide DNAm-MDP study that
used maternal tissue measured prenatal DNAm with the
HumanMethylation450 beadchip (450 k). No significant
results were found, possibly due to a modest sample size
(n = 38 antenatal maternal blood samples) [21] and
using only single probe approach. Modest sample sizes
are common in EWAS because of technology costs, but
regional analyses can mitigate power issues from small
sample sizes by reducing the multiple test burden. Ong
and Holbrook estimated that using their regional ap-
proach, a two-group 450 k study with 38 people (n = 19
per group) would have 61% power to identify results
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Table 2 Gene Ontology results for differentially methylated probes and regions
Ontology Description Gene ratio Bg ratio p value q value Gene ID
BP Cognition 11/136 284/17397 0.0000 0.038 TTC8/ADORA1/CNTNAP2/MEF2C/MEIS2/
NTSR1/PAFAH1B1/ADGRB3/RASGRF1/
SLC6A4/SYNGAP1
BP Learning or memory 9/136 246/17397 0.0001 0.114 CNTNAP2/MEF2C/MEIS2/NTSR1/
PAFAH1B1/ADGRB3/RASGRF1/SLC6A4/
SYNGAP1
BP Detection of
temperature stimulus involved in sensory perception
3/136 15/17397 0.0002 0.114 ADORA1/ARRB2/NTSR1
BP Detection of temperature stimulus involved in
sensory perception of pain
3/136 15/17397 0.0002 0.114 ADORA1/ARRB2/NTSR1
BP Dendrite development 8/136 216/17397 0.0003 0.114 CTNND2/COBL/MAP2/MEF2C/PAFAH1B1/
ADGRB3/KLF7/SYNGAP1
BP Detection of temperature stimulus 3/136 19/17397 0.0004 0.114 ADORA1/ARRB2/NTSR1
BP Modulation of chemical synaptic transmission 11/136 417/17397 0.0004 0.114 ADORA1/SYT9/ARRB2/MEF2C/NTSR1/
RASGRF1/SLC6A4/TMEM108/YWHAG/
SYNGAP1/CLSTN3
BP Regulation of trans-synaptic signal 11/136 418/17397 0.0004 0.114 ADORA1/SYT9/ARRB2/MEF2C/NTSR1/
RASGRF1/SLC6A4/TMEM108/YWHAG/
SYNGAP1/CLSTN3
BP Platelet formation 3/136 20/17397 0.0005 0.114 ZFPM1/MEF2C/MYH9
BP Establishment of cell polarity 6/136 128/17397 0.0005 0.114 SDCCAG8/SH3BP1/MAP2/MYH9/
PAFAH1B1/FRMD4A
BP Actin filament-based process 15/136 723/17397 0.0005 0.114 ABI2/ADORA1/DIAPH2/COBL/SH3BP1/
KCNJ5/MEF2C/MYH9/NEB/PAFAH1B1/
PLS3/LURAP1/ACTN4/MYOM2/TBCK
BP Platelet morphogenesis 3/136 21/17397 0.0006 0.114 ZFPM1/MEF2C/MYH9
BP Sensory perception of temperature stimulus 3/136 21/17397 0.0006 0.114 ADORA1/ARRB2/NTSR1
BP Behavior 13/136 579/17397 0.0006 0.116 ADORA1/CNTNAP2/KCND2/ARRB2/MEF2C/
MEIS2/NTSR1/PAFAH1B1/PEX13/ADGRB3/
RASGRF1/SLC6A4/SYNGAP1
BP Response to hypoxia 9/136 308/17397 0.0007 0.125 ADORA1/HILPDA/KCND2/LMNA/MMP2/
HIF3A/SLC6A4/TGFBR2/ACTN4
BP Regulation of postsynaptic membrane 6/136 139/17397 0.0008 0.128 ADORA1/KCND2/ARRB2/MEF2C/NTSR1/
TMEM108
BP Response to decreased oxygen levels 9/136 319/17397 0.0009 0.128 ADORA1/HILPDA/KCND2/LMNA/MMP2/
HIF3A/SLC6A4/TGFBR2/ACTN4
BP Chemical synaptic transmission 14/136 685/17397 0.0010 0.128 ADORA1/SYT9/GAD2/KCND2/ARRB2/
MEF2C/NTSR1/PAFAH1B1/RASGRF1/
SLC6A4/TMEM108/YWHAG/SYNGAP1/
CLSTN3
BP Anterograde trans-synaptic signaling 14/136 685/17397 0.0010 0.128 ADORA1/SYT9/GAD2/KCND2/ARRB2/
MEF2C/NTSR1/PAFAH1B1/RASGRF1/
SLC6A4/TMEM108/YWHAG/SYNGAP1/
CLSTN3
BP Establishment or maintenance of cell polarity 7/136 199/17397 0.0010 0.128 SDCCAG8/SH3BP1/LMNA/MAP2/MYH9/
PAFAH1B1/FRMD4A
BP Trans-synaptic signaling 14/136 693/17397 0.0011 0.134 ADORA1/SYT9/GAD2/KCND2/ARRB2/
MEF2C/NTSR1/PAFAH1B1/RASGRF1/
SLC6A4/TMEM108/YWHAG/SYNGAP1/
CLSTN3
BP Synaptic signaling 14/136 698/17397 0.0011 0.137 ADORA1/SYT9/GAD2/KCND2/ARRB2/
MEF2C/NTSR1/PAFAH1B1/RASGRF1/
SLC6A4/TMEM108/YWHAG/SYNGAP1/
CLSTN3
CC DNA repair complex 4/141 42/18363 0.0003 0.044 CETN3/ERCC1/PAXX/WRN
CC Neuron to neuron synapse 10/141 340/18363 0.0003 0.044 ADORA1/SYT9/CTNND2/KCND2/ARRB2/
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Table 2 Gene Ontology results for differentially methylated probes and regions (Continued)
Ontology Description Gene ratio Bg ratio p value q value Gene ID
MAP2/NTSR1/TMEM108/SYNGAP1/CLSTN3
CC Axon part 10/141 373/18363 0.0006 0.049 ADORA1/COBL/CNTNAP2/MAP2/NTSR1/
PAFAH1B1/TRPV2/RASGRF1/TMEM108/
RNF40
CC Synapse part 17/141 918/18363 0.0007 0.049 ADORA1/SYT9/CTNND2/GAD2/KCND2/
ARRB2/MAP2/MEF2C/NTSR1/COPS4/
ADGRB3/SLC6A4/TMEM108/YWHAG/
SYNGAP1/CLSTN3/RNF40
CC Cytoplasmic region 11/141 473/18363 0.0011 0.059 AKT2/FGF1/COBL/SH3BP1/MAP2/MYH9/
PAFAH1B1/CFAP46/TMEM108/ACTN4/
ARHGEF7
CC Distal axon 8/141 280/18363 0.0015 0.059 ADORA1/COBL/MAP2/NTSR1/PAFAH1B1/
TRPV2/RASGRF1/RNF40
CC Cell cortex 8/141 288/18363 0.0017 0.059 AKT2/FGF1/COBL/SH3BP1/MYH9/
PAFAH1B1/ACTN4/ARHGEF7
CC Actomyosin 4/141 71/18363 0.0022 0.059 MYH9/LURAP1/ACTN4/HDAC4
CC Dendrite 12/141 602/18363 0.0024 0.059 ADORA1/CTNND2/COBL/CNTNAP2/
KCNIP1/KCND2/ARRB2/MAP2/NTSR1/
TMEM108/URI1/SYNGAP1
CC Dendritic shaft 3/141 35/18363 0.0024 0.059 MAP2/NTSR1/SYNGAP1
CC Dendritic tree 12/141 604/18363 0.0024 0.059 ADORA1/CTNND2/COBL/CNTNAP2/
KCNIP1/KCND2/ARRB2/MAP2/NTSR1/
TMEM108/URI1/SYNGAP1
CC Postsynapse 12/141 604/18363 0.0024 0.059 ADORA1/CTNND2/KCND2/ARRB2/MAP2/
MEF2C/NTSR1/ADGRB3/SLC6A4/TMEM108/
SYNGAP1/CLSTN3
CC Postsynaptic density 8/141 315/18363 0.0030 0.059 ADORA1/CTNND2/KCND2/ARRB2/MAP2/
TMEM108/SYNGAP1/CLSTN3
CC Cell leading edge 9/141 389/18363 0.0032 0.059 ABI2/ADORA1/AKT2/COBL/SH3BP1/
CNTNAP2/MYH9/PAFAH1B1/ARHGEF7
CC Cell body 11/141 545/18363 0.0033 0.059 ADORA1/CTNND2/COBL/CNTNAP2/
KCND2/MAP2/NTSR1/PAFAH1B1/TRPV2/
TCP1/ARHGEF7
CC Asymmetric synapse 8/141 319/18363 0.0033 0.059 ADORA1/CTNND2/KCND2/ARRB2/MAP2/
TMEM108/SYNGAP1/CLSTN3
CC Somatodendritic compartment 14/141 818/18363 0.0042 0.069 ADORA1/CTNND2/COBL/CNTNAP2/
KCNIP1/KCND2/ARRB2/MAP2/NTSR1/
PAFAH1B1/TMEM108/URI1/SYNGAP1/
ARHGEF7
CC Dendrite terminus 2/141 13/18363 0.0043 0.069 COBL/MAP2
CC Postsynaptic specialization 8/141 339/18363 0.0047 0.069 ADORA1/CTNND2/KCND2/ARRB2/MAP2/
TMEM108/SYNGAP1/CLSTN3
CC Voltage-gated potassium channel complex 4/141 89/18363 0.0049 0.069 CNTNAP2/KCNIP1/KCND2/KCNJ5
CC Nucleotide-excision repair complex 2/141 14/18363 0.0050 0.069 CETN3/ERCC1
CC Axolemma 2/141 15/18363 0.0058 0.076 ADORA1/CNTNAP2
CC Axon 11/141 592/18363 0.0060 0.076 ADORA1/COBL/GAD2/CNTNAP2/MAP2/
NTSR1/PAFAH1B1/TRPV2/RASGRF1/
TMEM108/RNF40
CC Potassium channel complex 4/141 98/18363 0.0069 0.083 CNTNAP2/KCNIP1/KCND2/KCNJ5
CC Growth cone part 2/141 17/18363 0.0074 0.086 PAFAH1B1/TRPV2
CC Growth cone 5/141 165/18363 0.0090 0.100 COBL/MAP2/PAFAH1B1/TRPV2/RASGRF1
CC Site of polarized growth 5/141 167/18363 0.0094 0.101 COBL/MAP2/PAFAH1B1/TRPV2/RASGRF1
BP biological process, CC cellular component, Bg ratio background ratio
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with an effect size of 2 using a regional approach com-
pared to 39% with a single probe analysis [30]. This
power calculation does not map directly onto the ana-
lysis described here because Ong and Holbrook’s esti-
mate is for a case-control study design. This study used
a continuous measure of depression to avoid losing stat-
istical power from dichotomizing a naturally quantitative
trait. As a result, this study likely had at least 61% power
but may not have had 80%. Another benefit of regional
analyses is that the results are more likely to replicate
[30] in part because significant regional results require
multiple nearby probes each to have test statistics
greater than a chosen threshold and to exhibit the same
direction of effect. Together, the use of genome-wide
DNAm, a permutation rank-based approach for asses-
sing significance, and probes with test statistics either in
the upper or lower 2.5 percentile to test for DMRs each
positively influence the credibility of the results. Further,
the genomic locations of the significant DMRs increase
the credibility of the results as they overlap genes and
genomic regions that either directly corroborate previous
findings in the literature or that participate in biological
pathways hypothesized to be important for depression
risk or onset.
Another strength of this study concerns its design. Sig-
nificant care was taken to minimize potential biases and
confounders from biological, behavioral, and technical
factors. The women in this study completed multiple
comprehensive questionnaires about perinatal health
and behaviors, accessed prenatal care relatively early in
gestation, and were generally healthy (e.g., no diabetes)
[28], had healthy singleton pregnancies, and completed a
postpartum study visit within 7 months of delivery. These
study design aspects allow variation from behavioral, bio-
logical, and technical factors to be measured and
accounted for (e.g., cell type heterogeneity, tobacco use,
slide and positional effects, and signal quality). Addition-
ally, ancestrally-relevant principal components were incor-
porated to reduce the likelihood of detecting artifacts due
to potential population stratification. Visualization of me-
thyl values by self-reported race in significant DMRs sug-
gested that DNAm values did not differ markedly between
groups (see Additional file 4; Fig. 2).
Branching out to other depression phenotypes provides
both more literature for comparison, but also more uncer-
tainty. For example, it is not immediately clear if the DNAm
patterns associated with postpartum depressive symptoms
should resemble those associated with other depression phe-
notypes, including clinical major depression. Though both
are depression phenotypes, depressive symptoms and clin-
ical depression are not equivalent [60–63]. The issue of non-
equivalence emerged when comparing the findings in this
analysis to published results. For example, Numata
et al. reported a significant relationship between the
DNAm at cg14472315 and MD case status [25]. No sig-
nificant relationship existed between that probe and
self-reported postpartum depressive symptoms in this
study; however, a nominally significant relationship be-
tween that probe and lifetime history of MD was
present in this study (tested post hoc), reaffirming the
difficulty of comparing studies with related but non-
identical depressive phenotypes.
Fig. 1 Significant differentially methylated regions on chromosome 6 overlap findings from a Psychiatric Genomics Consortium meta-analysis of
depression. DNA methylation patterns associated with postpartum depressive symptoms (top row) and early-onset major depression (middle
row) colocalize to the major histocompatibility complex (MHC) region on chromosome 6. The overlap of the DNA methylation patterns and the
genomic region tagged in the genome-wide association meta-analysis of depression performed by the Psychiatric Genomics Consortium (PGC) is
shown in the bottom row [58]
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For all of its strengths, this study was not without limita-
tions. First, the sample size was modest, which limits the
statistical power to conduct robust single-site analysis.
The sample also included relatively few women with se-
vere levels of postpartum depressive symptoms, which
may have unique DNAm signatures compared to clinical
MDP. Moreover, this study could not determine if the
DNAm patterns identified in this study were a conse-
quence of previous episodes of MD (which is a risk factor
for perinatal depression [46]) or if they are related to other
genetic or environmental factors. Second, detailed infor-
mation about medication history was not available. Third,
the newness of the EPIC microarray means that the probe
set has been less well-vetted for cross-hybridization com-
pared to its predecessor [42, 64]. Four, regional analyses
are inherently limited because not all probes have the po-
tential to form regions [30]. This analysis attempted to ad-
dress that weakness by also performing a single site
analysis. Furthermore, the regional analysis algorithm used
in this study selected an equal number of probes with
positive and negative t values, corresponding to hyperme-
thylation and hypomethylation in cases versus controls.
This strategy assumes that equal representation of positive
and negative t values will yield the most fair results; how-
ever, it is possible that this assumption limited the number
of DMRs identified, especially if cases had much more
hyper- or hypomethylation. Finally, this study was limited
in its assessment of functional relevance. Multiple tech-
niques were used to assess gene set enrichment, but none
were specifically intended to correct for probe count per
region, leading to differences in enrichment results by
method. No gene expression, chromatin conformation, or
transcription factor binding assays were run concurrently
with postpartum DNAm analyses. No algorithms cur-
rently exist that can determine the precise change in
DNAm necessary to translate into biologically meaningful
differences in chromatin shape or gene regulation. As a re-
sult, fully understanding the etiology of MDP and depres-
sive symptoms will likely involve integrating repeated
measures from multiple biological layers (e.g., genetic se-
quence, epigenetic mechanisms, transcription, and pro-
tein) [65, 66], but no single study could measure every
biological layer that might be informative about depres-
sion etiology, especially not longitudinally.
Another important consideration for interpreting
DNAm results is the tissue source [29, 67]. It remains un-
clear how detrimental the use of peripheral blood DNAm
is for identifying genomic regions associated with a psy-
chiatric phenotype like depression. On one hand, specific
brain regions hold intuitive appeal for MD-DNAm stud-
ies, and the cross-tissue similarity between brain and
blood appears to be modest and tied to allelic variation
[68]; however, given the well-established link between MD
pathophysiology and aberrant immune system functioning
[34–36, 69], peripheral blood may be the best and most
feasible option for large or longitudinal studies of stress-
related psychiatric traits. Many of the biomarkers associ-
ated with MD are transported in the blood (e.g., IL-1, IL-
2, IL-6, TNFa, and haptoglobin), and some of these
immune-related differences appear to persist after depres-
sive episode remission. Not only does that observation fit
with epidemiological studies that find individuals with a
Fig. 2 Increases in depressive symptom load negatively correlate with DNA methylation in a significant region identified on chromosome 15. The
significantly differentially methylated region (row 2, “DMR”) was built using 5 of the 21 CpG probes available on the EPIC array (row 1, “EPIC”). The
mean group methyl values are shown for low, mid, and high depressive symptom loads based on Edinburgh Postnatal Depression Scale (EPDS)
total score (low = 0–4; mid = 5–12; high = 13 and greater). The threshold of 13 or greater for the high group was selected based on the
validated cutoff score for English-speaking women in the postpartum time period shortly following birth [31]
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positive lifetime history of MD remain sensitive to stress
and at higher risk for adverse auto-immune and cardiovas-
cular outcomes [34], but also it suggests that DNAm pat-
terns detectable in the blood may retain MD-associated
differences even after depressive episode remission. Last
but not least, peripheral blood may be useful for indexing
changes in the relationship between the CNS and immune
system. As a sentinel tissue, peripheral blood travels
throughout the entire body and can deliver immune cells
through the blood-brain barrier. Key players in the CNS
like the neurotransmitter serotonin also serve roles in
immune-related biological pathways (e.g., leukocyte acti-
vation and proliferation, cytokine secretion, chemotaxis,
and apoptosis) [36, 70]. The ability of the CNS to modu-
late and respond to signals from the immune system un-
derscores the intimate relationship between brain function
and immune system regulation.
The final category Michels et al. (2013) listed as an im-
portant factor in establishing the credibility of DNAm asso-
ciations with phenotypes is validation [29]. Validating
results typically implies either replicating the finding in an
independent study (human or animal) or confirming the
presence of differentially methylated probes and regions
using another technology (e.g., pyrosequencing). While no
pyrosequencing was completed, the literature was searched
extensively for associations between depressive phenotypes
and biological signatures (e.g., allelic, epigenetic, and tran-
scription). As previously mentioned, the genomic regions
implicated in this study overlap results from the 2018 Psy-
chiatric Genomics Consortium (PGC) genome-wide allelic
association study (GWAS) of MD [57] and are proximal to
significant regions and probes from an EWAS of early-
onset MD. Network analysis of the 44 significant loci in the
PGC meta-analysis implicated biological pathways associ-
ated with neural differentiation, synaptic regulation, risk for
schizophrenia, immune response, ion-gated channels, and
retinoid X receptors [57]. Similarly, this analysis identified
significant DMRs overlapping genes coding for or related
to retinoid X receptors (RXRB, ITGB3BP), genes integral to
adult neurogenesis and synaptic development and position-
ing (e.g., AKT2, SYNGAP1, FOXG1, CTNND2, MEF2C,
and AIMP1), risk for schizophrenia (e.g., CLSTN3, FARSB,
MYOM2, SOX2-OT, SLC39A7, SDCCAG8, and LRRC36),
immune response (LRR1, FAM19A2, CMKLR1, and
MMP2), and ion-gated channels and binding (e.g., SLC6A4,
SLC6A12, SLC39A7, KCNJ5, CLSTN3, and PLS3). While
these similarities do not serve as direct replication, they do
increase the credibility of the DNAm findings and under-
score the potential for DNAm studies to complement
GWA studies.
Conclusions
Future work should take note of the apparent differences in
depressive symptoms and clinical MD and seek to refine
association studies by limiting phenotypic heterogeneity.
For MDP, that means not only accounting for whether the
depressive symptoms or episodes onset prenatally versus
postnatally, but also disentangling which DNAm patterns
are associated with perinatal depressive phenotypes and
which reflect pre-pregnancy events of depressive psycho-
pathology. It is possible that women who experience their
first instance of MD in the peripartum have a unique
DNAm profile compared to those who have recurrent MD
and happen to onset during the peripartum. Furthermore,
it is unknown whether an episode of MD relatively early in
life evokes a persistent perturbation in DNAm patterning
that then goes on to affect the risk for additional depressive
symptoms and episodes as well as other adverse health out-
comes frequently comorbid with depression (e.g., cardiovas-
cular disease and diabetes mellitus). Clarifying the
phenotypes associated with DNAm patterns will enable wet
lab researchers to characterize the functional and biological
relevance of implicated genomic sites and regions, which is
an essential step not only for understanding the biological
mechanisms associated with risk and resilience to depres-
sive psychopathology but also for developing screening tests
and identifying novel pharmacotherapeutic targets.
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Additional file 1. DMP-only and DMR-only gene enrichment analysis.
This file contains gene ontology enrichment results in tabular format for
the combined set of differentially methylated regions and probes (DMR,
DMP) results, enrichment analysis of DMRs only, and enrichment analysis
of DMPs only. CSV files for these results are on the Open Science Frame-
work (OSF; landing page https://osf.io/qsc6n).
Additional file 2. List of genes overlapping differentially methylated
regions. List of the 92 genes overlapped by significant differentially
methylated regions (DMRs).
Additional file 3. Enrichment testing of Psychiatric Genomic
Consortium (PGC) supplemental methods. This file contains additional
details about how the 95% confidence intervals were calculated for the
PGC enrichment analysis.
Additional file 4: Supplement to Figure 2. This file contains two
additional versions of the differentially methylated region (DMR)
highlighted in Fig. 2. The top figure shows the ComBat-adjusted methyl
values for each participant colored by self-identified Census-based race
category. The points have been jittered left/right to ease visualization by
reducing over-plotting. No vertical adjustment was made. The bottom
figure shows the mean methyl values for each probe contained in the
DMR by self-identified Census-based race category.
Additional file 5. Additional Figures. This file contains four figures:
quantile-quantile plots for the DMP and DMR analyses and histograms of
the distribution of when PREG postpartum study visits occurred (i.e., time
since birth) and the distribution of EPDS total scores by self-reported life-
time history of MD (assessed using an extended self-report version of the
CIDI-SF).
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